# US 2026/0091020 A1 · Treatment of acute cannabinoid overdose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091020 A1
- Document ID: US20260091020A1
- Status: Published application
- Kind: A1
- Application number: 19/113,693
- Filed: 2023-09-25
- Published: 2026-04-02
- Earliest claimed: 2022-09-26
- Assignees: Anebulo Pharmaceuticals, Inc.
- Applicants: Anebulo Pharmaceuticals, Inc.
- Inventors: Joseph Fenton LAWLER; Daniel Pawel SCHNEEBERGER; Kenneth C. CUNDY
- Web page: https://patentgrep.com/patent/US20260091020A1

## CPC

- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating cannabinoid intoxication. Further provided herein are metrics for evaluation Cannabis intoxication and the amelioration thereof.

## Claims

### Claim 1

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein treating improves one or more metrics associated with acute cannabinoid intoxication.

### Claim 2 (depends on 1)

The method of claim 1, wherein the improvement is measured between a first time before administration of the compound and a second time after administration of the compound.

### Claim 3 (depends on 2)

The method of claim 2, wherein the difference between the first time and the second time is 30 minutes to 8 hours.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the time between pre-administration and post administration of the compound is 30 minutes to 4 hours.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the metric comprises one or more of impaired motor coordination, and euphoria.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the metric comprises heartrate, loss of alertness, body movement, or visual analog scale (VAS) assessment of cannabinoid intoxication.

### Claim 7 (depends on 6)

The method of claim 6, wherein the loss of alertness caused by cannabinoid intoxication is reduced by at least about 20%.

### Claim 8 (depends on 6)

The method of claim 6, wherein loss of alertness is measured by the subject's responses to one or more questions asked by a healthcare provider or emergency responder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the one or more questions are directed to one or more of mood and feelings.

### Claim 10 (depends on 9)

The method of claim 9, wherein the one or more questions are directed to one or more of alertness/fuzzy/clearheaded, coordinate/clumsy, lethargic/energetic, contented/discontented, troubled/tranquil, mentally slow/quick witted, tense/relaxed, attentive/dreamy, drowsy, calm/excited, strong/feeble, incompetent/proficient, happy/sad, antagonistic/friendly, interested/bored, withdrawn/sociable, self-centered/outward going or depressed/elated.

### Claim 11 (depends on 6)

The method of claim 6, wherein the loss of alertness caused by cannabinoid intoxication is reduced by at least one level.

### Claim 12 (depends on 6)

The method of claim 6, wherein the loss of alertness caused by cannabinoid intoxication is reduced by at least 10%.

### Claim 13 (depends on 6)

The method of claim 6, wherein level of alertness is scored from using best verbal response.

### Claim 14 (depends on 6)

The method of claim 6, wherein body movement comprises body sway.

### Claim 15 (depends on 6)

The method of claim 6, wherein body sway is measured as a distance.

### Claim 16 (depends on 6)

The method of claim 6, wherein body sway comprises antero-posterior sway (mm).

### Claim 17 (depends on 6)

The method of claim 6, wherein body sway distance is measured using a Wright ataxiameter.

### Claim 18 (depends on 6)

The method of claim 6, wherein the distance of body sway distance caused by cannabinoid intoxication is reduced by at least about 25%.

### Claim 19 (depends on 6)

The method of claim 6, wherein VAS comprises measurement of one or more of alertness, negative affect, calmness, feeling high, and external perception.

### Claim 20 (depends on 6)

The method of claim 6, wherein VAS comprises measurement of one or more of the sixteen items in the Bond & Lader scales.

### Claim 21 (depends on 1)

The method of claim 1, wherein the metric is measured by a healthcare provider or emergency responder.

### Claim 22 (depends on 1)

The method of claim 1, wherein the metric is self-reported by the subject.

### Claim 23

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a plasma Cmax of about 100-500 ng/mL.

### Claim 24

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a plasma AUClast of about 500-2800 h*ng/mL.

### Claim 25

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a plasma AUC5h of about 100-1200 h*ng/mL.

### Claim 26

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a dose normalized plasma Cmax of about 3-20 ng/mL/mg.

### Claim 27

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a dose normalized plasma AUClast of about 50-400 h*ng/mL/mg.

### Claim 28 (depends on 27)

The method of claim 27 wherein the compound has a dose normalized plasma AUClast of about 50-200 h*ng/mL/mg.

### Claim 29

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a dosage normalized plasma AUC5h of about 10-40 h*ng/mL/mg.

### Claim 30

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein the compound has a Tmax of or less than about 60 minutes.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the amount of compound administered to the subject is 1-200 mg, 10-50 mg, 10-30 mg, or 20-30 mg.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the method further comprises administering 5-300 mg, 5-100 mg, or 10-30 mg of delta-9-tetrahydrocannabinol (THC) to the subject.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the THC and the compound are administered at the same time.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the THC is administered 10 min to 8 hours before the compound is administered.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the administration is oral.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the compound is administered as a capsule.

### Claim 37 (depends on 36)

The method of claim 36, wherein the capsule comprises a soft gel capsule.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37 wherein the acute cannabinoid intoxication results from ingestion of an edible form of Cannabis.

### Claim 39

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound having the structure
wherein treating accelerates recovery, shortens time in medical care or reduces the effects the intoxication as determined by an acceptable metric evaluation.

### Claim 40

A composition comprising a compound having the structure:

### Claim 41 (depends on 40)

The composition of claim 40, wherein the compound is a salt, polymorph, solvate, hydrate, stereoisomer, or isotope thereof.

### Claim 42 (depends on 40)

The composition of claim 40, wherein the compound is a solid.

### Claim 43 (depends on 40)

The composition of claim 40, wherein the compound is a crystalline solid.

### Claim 44 (depends on 40)

A pharmaceutical composition comprising the compound of claim 40 and a pharmaceutically acceptable excipient.

### Claim 45 (depends on 40)

An oral dosage form of the compound of claim 40 and a pharmaceutically acceptable excipient.

### Claim 46 (depends on 40)

An injectable dosage form of the compound of claim 40 and a pharmaceutically acceptable excipient.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45, 46)

A method of treating a known or suspected acute cannabinoid intoxication in a subject in need thereof, the method comprising: administering to the subject a therapeutically-effective amount of a compound of any one of claims 40-46.
